SGHT (Sight Sciences) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGHT Sight Sciences Inc SGHT
72 GF Score
Price $5.05
GF Value $4.51
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

SGHT
72GF Score
Sight Sciences Inc SGHT
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.05 is trading 12% above its estimated GF Value™ of $4.51. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • Interest Received:
  • GF Value™: $4.51 vs. price of $5.05 (12% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score

Get the complete analysis for SGHT

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.05
Price
$4.51
GF Value